Advancing mental health care through enhanced neural plasticity.

Psychiatric disorders have become a severe burden on society. In Europe alone, an estimated 90M people are living with depression. For those people, the standard treatment options remain to be antidepressants which have now been in use for over 50 years. These options are no longer good enough, where over 50% of people will relapse and over 30% of patients will receive no benefit at all. However, new therapies are beginning to offer hope in the treatment of psychiatric disorders by focusing their efforts on promoting neural plasticity, enabling the brain to form new connections and remodel itself.

​​While researching alternative therapies in this space, Syntropic's founders, in Venturino et al., 2021, made a breakthrough discovery whereby the therapeutic effect of ketamine could be replicated using a non‑pharmaceutical and non‑invasive approach. This demonstration, in vivo, showed that Syntropic’s light based therapy reduces symptoms of depression and promotes cognitive function. This was achieved without any side effects, free of pharmaceuticals, and at low cost. The team is now moving forward with clinical development to deliver this technology to those who need it most.

For patients who fail to receive the clinical benefit and/or struggle with the side‑effects of existing therapies, Syntropic offers a new and novel solution that has the potential to provide long‑lasting relief from psychiatric illness. With a focus on accessibility, affordability and patient‑usability, the solution offers significant benefits to both patients and healthcare systems. Syntropic aims to transform the landscape of mental health care through the advancement of health technology for the unmet needs of patients.